TD Newcrest upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy.

TD analyst says, "We are upgrading Valeant in consideration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE